Digoxin Use and Adverse Outcomes in Patients With Atrial Fibrillation

Wu-Tao Zeng, MD, PhD, Zhi-Hao Liu, MD, PhD, Zhu-Yu Li, MD, Ming Zhang, MD, PhD, and Yun-Jiu Cheng, MD

Abstract: Digoxin has long been used for rate control in atrial fibrillation (AF); its safety remains controversial. We performed a literature search using MEDLINE (source PubMed, January 1, 1966, to July 31, 2015) and EMBASE (January 1, 1980, to July 31, 2015) with no restrictions. Studies that reported relative risk (RR) estimates with 95% confidence intervals (CIs) for the associations of interest were included. Pooled effect estimates were obtained by using random-effects meta-analysis. Twenty-two studies involving 586,594 patients were identified. Patients taking digoxin, as compared with those who took no digoxin, experienced an increased risk of death from any cause (RR: 1.29 [95% CI 1.16–1.43]), even after reported adjustment for propensity scores (RR: 1.28 [95% CI 1.18–1.39]). The risk of death was increased with patients with or without heart failure (RR: 1.12 [95% CI 1.02–1.23] and RR: 1.26 [95% CI 1.15–1.29], respectively), and patients taking or not taking beta blockers (RR: 1.17 [95% CI 1.06–1.30] and RR: 1.28 [95% CI 1.08–1.51], respectively). Digoxin use was also associated with increased risk of cardiovascular death (RR: 1.32 [95% CI 1.07–1.64]), arrhythmic death (RR: 1.38 [95% CI 1.07–1.79]), and stroke (RR: 1.20 [95% CI 1.00–1.44]). Digoxin treatment is associated with an absolute risk increase of 19 (95% CI 13–26) additional deaths from any cause per 1000 person-years. Digoxin use is associated with a significant increased risk for death from any cause in patients with AF. This finding suggests a need for reconsideration of present treatment recommendations on use of digoxin in AF.

(Medicine 95(12):e2949)

Abbreviations: AF = atrial fibrillation, CI = confidence interval, HF = heart failure, RCT = randomized clinical trials, RR = relative risk.

INTRODUCTION

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia encountered in clinical practice, affecting >33.5 million individuals worldwide.1 AF increases the risk of stroke, congestive heart failure (HF), ventricular arrhythmias, and death. A key treatment target in AF is heart rate control, which might help reduce symptoms and the risk of HF.2 During the past 2 centuries, digoxin remains one of the most widely used rate control agent worldwide and is largely accepted as a valid therapeutic option for AF. Current American Heart Association, American College of Cardiology, and Heart Rhythm Society treatment guidelines for the management of AF recommend the use of digoxin alone for resting heart rate control in sedentary individuals (Class I recommendation, level of evidence C).3

Although considered generally safe, several recent studies have reported digoxin to have potential proarrhythmic properties, long-term effects on cardiac remodeling, and even link to adverse prognosis in AF.3,4 Actually, evidence from large cohort studies and post-hoc analyses of randomized clinical trials (RCTs) to assess a potential increase in serious cardiac events associated with digoxin is conflicting. Some studies have found no significant association between digoxin use and mortality,5,6 whereas other studies recently showed that digoxin was associated with increased risk for death from any cause and cardio-vascular death in patients with AF 7–9. Interpretation of the evidence has been complicated by populations with different baseline characteristics (e.g., men vs women; concurrent with HF versus without HF; concomitant use of beta blockers vs no use of beta blockers; baseline use of digoxin vs incident use of digoxin), and different studies types (retrospective cohort studies vs prospective cohort studies versus RCTs). There is therefore a clear imperative to define the place of digoxin in the clinical management of AF and to guide physicians and patients with an indication for treatment with digoxin. Thus, we conducted a meta-analysis to examine the link between digoxin and adverse outcomes, including death from any cause, cardiovascular death, arrhythmic death, and stroke.

METHODS

Search Strategy

We undertook a meta-analysis of the published work without language restrictions according to the PRISMA guidelines (Appendix Text 1, http://links.lww.com/MD/A833). We selected relevant studies published in the electronic databases MEDLINE (source PubMed, January 1, 1966, to December 31, 2015) and EMBASE (January 1, 1980, to December 31, 2015) with the following combined text and MeSH heading search strategy: “digoxin,” “mortality,” “death,” “cardiovascular,” “cardiac,” “atrial fibrillation.” We also manually scrutinized the references of all relevant articles to supplement our search.

DOI: 10.1097/MD.0000000000002949
Study Selection

Studies were considered eligible if they met the following criteria: (1) the study designs were cohort studies, case-control studies or RCTs (animal studies, cross-sectional studies, reviews, commentaries, letters, and studies that examined other associations were excluded); (2) the outcome of interest was death from any cause, cardiovascular death, arrhythmic death or stroke; and (3) relative risk (RR) and the corresponding 95% confidence interval (CI) or data to calculate them were reported; (4) studies were independent. We reviewed each publication and only the most recent or complete study was included when multiple reports on the same population or subpopulation were identified.

Data Abstraction and Quality Assessment

Three authors (WTZ, ZHL, ZYL) extracted the following information from each study: study’s characteristics (study design, first author’s name, publication year, geographical area, duration of follow-up, sample size and numbers of incident cases), participants’ characteristics (mean age and gender category) and analysis strategy (statistical models, confounders adjusted for, effect sizes and 95% CIs). Methodological Index for Non-Randomized Studies (MINORS) was used to evaluate the quality of all studies. Studies received 0 point to 2 points for each of these 12 components. Total score ranged from 0 point to 24 points. Studies were defined to be low-quality and high-quality studies based on their MINORS scores of <16 and ≥16 points.16

Statistical Analysis

The RRs were used as the common measure of association across studies. Summary RRs were estimated by pooling the study-specific estimates using random rather than fixed effects models in order to take into account the between-study heterogeneity.11 To assess for heterogeneity of RRs across studies, the $I^2$ (95% CI) statistic was calculated with the following interpretation: low heterogeneity defined as $I^2<50%$; moderate heterogeneity defined as $I^2 50% to 75%; high heterogeneity defined as $I^2>75%$.12 Heterogeneity was also calculated by comparing results from studies stratified according to prespecified study-level characteristics with meta-regression and subgroup analyses.13 Sensitivity analysis was performed to assess the effects of selected study quality. Possible publication bias was assessed by using Begg’s adjusted rank correlation test and Egger’s regression asymmetry tests and by visual inspection for asymmetry of a funnel plot of the natural logarithms of the effect estimates against their standard errors.14 We did all analyses with Stata version 11.0 (Stata Corp) and a $P$ value<0.05 was considered statistically significant.

RESULTS

Study Selection

With the search strategy, 1309 unique citations were initially retrieved. Of these, 268 articles were considered of interest and full text was retrieved for detailed evaluation. Two hundred and twenty-one articles were excluded with no relevant outcomes, and other 25 articles were excluded because they did not provide enough data to estimate RR, leaving 22 studies for final inclusion in the meta-analysis (Appendix Figure 1, http://links.lww.com/MD/A833).

Study Characteristics

A total of 586,594 patients were included in 22 eligible studies, of which 62.3% were men. Seven studies were based in Europe, 7 in North America, 3 in East Asia, and 5 were multinational. There were 11 retrospective cohort studies, 6 prospective cohort studies and 5 retrospective of RCTs. Of the primary studies, 100% had described independent, consecutive sampling of their cohort. Average follow-up duration ranged from 6.0 to 56.4 months. Patients were followed up for an average of >24 months in a majority of studies (62.5%). The sizes of the cohorts ranged from 347 to 220,068, with the 3 largest studies including patients >100,000. Digoxin use was defined as baseline use in 18 studies, and as incident use in 6 studies (Appendix Table 1, http://links.lww.com/MD/A833). Five of the 22 studies reported data on the daily digoxin dose and/or the mean digoxin plasma levels (Appendix Table 2, http://links.lww.com/MD/A833). The end-point of death from any cause was reported in 21 studies, cardiovascular death was reported in 8 studies, arrhythmic death was reported in 5 studies, and stroke was reported in 7 studies, respectively. Adjusted RRs could be determined for all studies, with 11 studies reporting adjusted estimates for propensity scores (Appendix Table 1, http://links.lww.com/MD/A833). The methodological quality of the included studies was generally good, with MINORS scores >16 points in all the studies included (Appendix Table 3, http://links.lww.com/MD/A833).

Association With Death From any Cause

Twenty-one studies with data of 573,114 individuals and at least 225,453 events reported risk estimates for death from any cause. Among the 21 selected studies, all but 2 found an association between use of digoxin and an increased risk of death from any cause, although not all were statistically significant. Overall, patients with AF taking digoxin compared with the reference group experienced a significantly increased risk for death from any cause (RR: 1.29 [95% CI 1.16–1.43, P<0.001]) (Figure 1). From studies that reported information on person-years in patients taking and not taking digoxin, we could calculate absolute annual rates of death from patients with AF: 73 deaths per 1000 person-years in patients taking digoxin and 54 deaths in patients not taking digoxin, corresponding to an absolute risk increase of 19 (95% CI 13–26) deaths per 1000 person-years.

Sensitivity analysis using a fixed-effects instead of random-effects model yielded similar results (RR: 1.37 [95% CI 1.35–1.39, P<0.001]). In addition, risk estimates changed little after exclusion of 3 largest studies with sample size >100,000 or 2 outlier studies reporting largest RRs. Only 5 studies reported digoxin dosing and/or plasma levels, and restricting analyses to these studies showed a somewhat greater risk (RR: 1.57 [95% CI 1.09–2.27, P<0.001]). Of note, when the analysis was confined to those studies with propensity matched cohort (high quality), the overall combined RR did not appreciably change (RR: 1.28 [95% CI 1.18–1.39, P<0.001]) (Table 1).

There was evidence of considerable heterogeneity of RRs across these studies (I 2: 96.39% [95% CI 95.40–97.16%, P<0.001]) (Figure 1). These measurements of heterogeneity were likely driven by the extremely large overall number of participants in our analysis (> 500,000). The point estimates of the RRs were consistently >1 in all but 2 studies, and study subgroups were more homogeneous. Neither funnel plots nor Egger and Begg tests showed evidence of publication bias (Egger, P = 0.10; Begg, P = 0.49) (Appendix Figure 2, http://links.lww.com/MD/A833).

Stratified Analyses

To further explore study heterogeneity, we performed stratified analyses across a number of key study characteristics...
and clinical factors. The finding of increased risk of death from any cause associated with digoxin was consistently observed in all of the stratified analyses. Study quality characteristics did not seem to markedly influence the results. Follow-up duration (P = 0.46), geographical area (P = 0.95), number of events (P = 0.56), or publication year (P = 0.46) were not significantly associated with the strength of the association. Stronger associations between digoxin and risk of death from any cause were found in studies that were adjusted for 8 or more confounding factors, but these differences were not statistically significant (P = 0.68). Of note, similar results were observed in retrospective cohort studies (RR: 1.32 [95% CI 1.14–1.52]), prospective cohort studies (RR: 1.31 [95% CI 1.10–1.58]), and post-hoc analysis of RCTs (RR: 1.25 [95% CI 1.15–1.36]) (Table 2).

**TABLE 1.** Sensitivity and Heterogeneity Analysis of Pooled Relative Risks of Death From any Cause Associated With Digoxin in Patients With Atrial Fibrillation

| Studies, n | RR (95% CI) | I² (95% CI) |
|------------|-------------|-------------|
| Statistical model | | |
| Random effects | 21 | 1.29 (1.16–1.43) | 96.39 (95.40–97.16) |
| Fixed effect | 21 | 1.37 (1.35–1.39) | 96.39 (95.40–97.16) |
| Analysis of all studies with | | |
| Adjustment for propensity scores | 11 | 1.28 (1.18–1.39) | 84.66 (74.18–90.88) |
| Data on digoxin dosing and/or plasma levels | 5 | 1.57 (1.09–2.27) | 73.63 (34.31–89.42) |
| Analysis of all studies except | | |
| Three largest studies* | 18 | 1.28 (1.15–1.42) | 74.63 (59.77–84.00) |
| Two outlier studies† | 19 | 1.25 (1.13–1.39) | 96.71 (95.79–97.43) |

CI = confidence interval, RR = relative risk.

*Large cohort studies with sample size >100,000.
†Studies with largest RR by Pastori D and PALLAS trial.
increased risk of stroke for patients with AF (RR: 1.20 [95% CI 1.004–1.44, P = 0.045]) (Figure 2). However, digoxin did not seem to be associated with risks of HF hospitalization, acute myocardial infarction, and all-cause hospitalization (Appendix Figure 3, http://links.lww.com/MD/A833).

DISCUSSION

The present meta-analysis, involving >500,000 participants from 22 studies, found a significantly increased risk of death from any cause associated with digoxin therapy in patients with AF, even after reported adjustment for propensity scores. These observations were consistent across all subgroups and were independent of age, sex, HF, definition of digoxin therapy, or concomitant therapy with beta-blockers. Digoxin therapy also increases risk of cardiovascular death, arrhythmic death and stroke. In terms of absolute risk, use of digoxin would account for an estimated 19 deaths per 1000 person-years. These findings challenge the current cardiovascular society guidelines, which give Class I and Class IIa recommendations for the use of digoxin as an adjunct to rate control monotherapy.

There is 1 factor that may confound the interpretation of association between digoxin therapy and risk of mortality. Patients with more advanced HF, hospitalization, or more recalcitrant AF are more likely to be prescribed digoxin, which is likely to associate digoxin with worse clinical outcomes. In light of the absence of RCTs testing digoxin in patients with AF, observational studies, and post-hoc analyses of RCTs may be of

| TABLE 2. Stratified Analyses of Pooled Relative Risks of Death From any Cause Associated With Digoxin in Patients With Atrial Fibrillation |
|---------------------------------------------------------------|
| **Factors Stratified** | **Studies** | **Events** | **Patients** | **Pooled RR (95% CI)** | **I² (95% CI)** | **P for Interaction** |
| Study quality characteristics | | | | | | |
| Type of studies | | | | | | |
| Retrospective cohort | 10 | 219,286 | 510,011 | 1.32 (1.14–1.52) | 98.26 (97.69–98.69) | 0.58 |
| Prospective cohort | 6 | 3707 | 35,955 | 1.31 (1.10–1.58) | 63.77 (12.39–85.02) | 0.46 |
| Follow up analysis of RCT | 5 | 2460 | 27,148 | 1.25 (1.15–1.36) | 77.91 (46.88–90.82) | 0.46 |
| Follow up | | | | | | |
| <30 months | 10 | 6416 | 74,688 | 1.34 (1.17–1.53) | 76.86 (57.37–87.44) | 0.46 |
| ≥30 months | 11 | 219,037 | 498,426 | 1.24 (1.08–1.44) | 98.06 (97.43–98.53) | 0.46 |
| Location | | | | | | |
| North America | 7 | 111,031 | 291,844 | 1.29 (1.18–1.41) | 87.37 (76.26–93.28) | 0.95 |
| Europe | 7 | 111,467 | 247,826 | 1.30 (1.07–1.57) | 90.27 (82.51–94.59) | 0.95 |
| Asia | 2 | 989 | 6797 | 1.21 (1.02–1.43) | 67.19 (16.75–87.54) | 0.95 |
| Multi-national | 5 | 1966 | 26,647 | 1.27 (1.05–1.54) | 67.19 (16.75–87.54) | 0.95 |
| Events, n | | | | | | |
| <1000 | 14 | 4060 | 37,229 | 1.26 (1.10–1.43) | 63.36 (34.90–79.38) | 0.55 |
| ≥1000 | 7 | 221,393 | 535,885 | 1.33 (1.14–1.55) | 98.83 (98.41–99.14) | 0.55 |
| Publication year | | | | | | |
| <2010 | 7 | 4230 | 34,657 | 1.23 (1.06–1.43) | 73.86 (44.08–87.78) | 0.46 |
| ≥2010 | 14 | 221,223 | 538,457 | 1.32 (1.16–1.51) | 97.53 (96.79–98.11) | 0.46 |
| Adjustment for confounding factors | | | | | | |
| Minimal (<7 factors) | 9 | 3668 | 33,913 | 1.26 (1.10–1.43) | 73.36 (44.90–79.38) | 0.55 |
| Substantial (≥8 factors) | 12 | 221,785 | 539,201 | 1.31 (1.15–1.49) | 97.89 (97.22–98.39) | 0.55 |
| Patient characteristics | | | | | | |
| Age, y | | | | | | |
| <75 | 4 | 15,198 | 74,007 | 1.40 (1.06–1.86) | 84.42 (60.97–93.78) | 0.71 |
| ≥75 | 5 | 94,654 | 212,443 | 1.28 (1.18–1.39) | 86.34 (70.22–93.73) | 0.71 |
| Sex category | | | | | | |
| Men | 6 | 18,508 | 174,304 | 1.36 (1.23–1.49) | 87.37 (74.87–93.65) | 0.81 |
| Women | 6 | 19,387 | 52,255 | 1.33 (1.14–1.55) | 79.87 (56.26–90.74) | 0.81 |
| Digoxin use | | | | | | |
| Baseline use | 17 | 194,757 | 430,865 | 1.27 (1.11–1.44) | 96.66 (95.66–97.43) | 0.60 |
| Incident use | 6 | 32,085 | 158,365 | 1.33 (1.15–1.54) | 84.99 (69.16–92.69) | 0.60 |
| Treated with beta blockers | | | | | | |
| Yes | 8 | 118,865 | 300,345 | 1.17 (1.06–1.30) | 80.97 (63.40–90.11) | 0.04 |
| No | 8 | 114,337 | 282,418 | 1.28 (1.08–1.51) | 96.47 (94.72–97.64) | 0.04 |
| History of heart failure | | | | | | |
| Yes | 11 | 29,424 | 72,504 | 1.12 (1.02–1.23) | 84.86 (74.57–90.99) | 0.03 |
| No | 7 | 78,596 | 219,731 | 1.26 (1.15–1.29) | 63.68 (17.83–83.95) | 0.03 |
| History of coronary disease | | | | | | |
| Yes | 3 | 1664 | 9493 | 1.37 (1.10–1.70) | 62.26 (0.89–23) | 0.80 |
| No | 3 | 27,696 | 122,107 | 1.31 (1.12–1.54) | 37.69 (0.80–40) | 0.80 |

CI = confidence interval, RCT = randomized clinical trials, RR = relative risk.
particular utility for evaluating this association, despite risk of bias and confounding by indication still exists. However, in the analysis of studies with propensity matched cohort and post-hoc analyses of RCTs that provide more robust control for confounders than adjustment, the results were similar to the main findings. Of interest, we did not note increased risk with digoxin with respect to other adjudicated endpoints such as HF hospitalization, acute myocardial infarction and all cause hospitalization, reducing the likelihood of significant unmeasured confounding factors. In addition, similar results were observed in studies that focused on death associated with incident digoxin therapy to avoid biases associated with examining prevalent therapy and outcomes and captured longitudinal exposure to digoxin throughout follow-up. These indicate that risk of mortality associated with digoxin might be attributable to the prescribed treatment rather than the effect of disease severity.

The underlying mechanisms involved in the association between digoxin therapy and adverse outcomes in patients with AF are uncertain. However, several plausible explanations have been suggested. First, our results indicated that the death risk associated with digoxin might be partly mediated by its cardiovascular toxicity, supported by the evidence that risks of cardiovascular death and arrhythmic death were both increased. It is well appreciated that digoxin has a narrow therapeutic window. Freeman et al, demonstrated in the ATRIAL-CVRI study that levels of digoxin serum concentration were significantly higher in patients who died compared with those who did not die (1.515 ng/mL vs 0.935 ng/mL, \( P < 0.001 \)).\(^4\) Digoxin may provoke paroxysmal atrial tachycardias and relapses of AF by promoting atrial reverse remodeling, modulating intracellular calcium signaling, and triggering oxidative stress.\(^3,15–18\) In addition, digoxin might also provoke serious bradycardia such as severe sinus bradycardia and high-degree atrio-ventricular block, and ventricular arrhythmias such as ventricular tachycardia, torsades de pointes, and ventricular fibrillation; these arrhythmias may be facilitated by coexistence of electrolyte imbalances (i.e., hypokalemia, hypomagnesemia, and hypercalcemia) and/or unrecognized atrio-ventricular accessory pathways.\(^19\) Second, it is theoretically possible for digoxin to increase noncardiac deaths, similar to the association between amiodarone and cancer deaths reported in a prior AFFIRM substudy.\(^20\) It is also possible that digoxin might cause noncardiac side effects such as anorexia, nausea, and vomiting and further accentuated by significant drug–drug interactions, such as clarithromycin, dronedarone, amiodarone, propafenone, or verapamil, all of which can increase serum digoxin concentrations and may increase the likelihood of digoxin toxicity.\(^21,22\) Third, why would digoxin

---

**FIGURE 2.** Forest plot showing relative risks of cardiovascular death, arrhythmic death, and stroke associated with digoxin therapy in patients with atrial fibrillation. The size of each square is proportional to the study’s weight (inverse of variance).
therapy increase risk of stroke in patients with AF? Digoxin could inhibit the Na+/K+ -ATPases, which, in turn, leads to increased levels of intracellular calcium. And activation of platelets by increased intracellular calcium levels may enhance thrombogenesis and thus the risk of ischemic stroke.18

Strengths of this meta-analysis include the strict inclusion criteria, the large number of patients analyzed, the robustness of the findings in sensitivity analyses, and the fact that all subgroup analyses were prespecified a priori. There are several limitations to this study. First, there is a clear and understandable discrepancy in the sample sizes from randomized and observational data. Second, there is anticipated heterogeneity of RRs among studies in the primary analysis and we therefore prespecified a random effects model, which may produce more conservative results. However, stratified analyses showed pooled RRs consistently >1 across a number of clinical factors. In addition, the consistency of the finding of an increased risk of death from any cause with digoxin therapy in both cohort studies and post-hoc analyses of RCTs suggests that the association is valid. Third, AF has a wide clinical spectrum, from asymptomatic disease to a severe uncontrolled condition. Definitions of AF in different studies varied, and we cannot exclude misclassification. Fourth, another limitation was the lack of individual participant data, which precluded determining the independent associations of individual variables with study outcomes. For example, the previous study suggested higher serum digoxin levels were significantly associated with increased mortality. Limited data on dosing or serum concentration of digoxin in original studies make it impossible to analyze the effect of high digoxin doses and serum concentrations on outcomes, including cardiovascular death and arrhythmic death. Fifth, like all meta-analyses, our study has the limitation of being a retrospective analysis. In absolute terms, an addition of 19 deaths from any cause occurred per 1000 patients per year associated with digoxin in this study. Given that the absolute risk is not small and that digoxin remains commonly used for the heart rate control in patients with AF around the world, the total number of excess deaths may not be negligible. This calls for large well-designed RCTs of dose-adjusted digoxin therapy in AF patients. In light of this finding and the availability of other drugs for rate control in patients with AF, such as beta-blockers and nondihydropyridine calcium channel antagonists, digoxin treatment might be used with caution in patients with AF until such proper RCTs are being completed.

In conclusion, the results from this meta-analysis suggest that in patients with AF, treatment with digoxin was independently associated with increased risk of death from any cause, as well as cardiovascular death, arrhythmic death, and stroke. These results were consistent across strata of age, sex, HF status, or concomitant therapies. Given other available rate control options, digoxin might be used with caution in the management of AF until such proper RCTs are being completed.

REFERENCES

1. January CT, Wann LS, Alpert JS, et al. 2014AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–e76.
2. Camm AJ, Savelieva I, Lip GY. Rate control in the medical management of atrial fibrillation. Heart. 2007;93:35–38.
3. Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28:527–555.
4. Freeman JV, Reynolds K, Fang M, et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8:49–58.
5. Okin PM, Hille DA, Wachtell K, et al. Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. J Hypertens. 2015;33:1480–1486.
6. Wang J, Yang YM, Zhu J, et al. Analysis of risk factors for all-cause mortality in Chinese emergency atrial fibrillation patients. Zhonghua Yi Xue Za Zhi. 2013;93:2871–2875.
7. Allen LA, Fonarow GC, Simon DN, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2691–2698.
8. Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385:2363–2370.
9. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660–668.
10. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–716.
11. Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke. 2015;46:157–163.
12. Cheng YJ, Liu ZH, Yao FJ, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013;10:e1001515.
13. Cheng YJ, Nie XY, Chen XM, et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol. 2015;66:2173–2184.
14. Cheng YJ, Zhang J, Li WJ, et al. More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol. 2014;7:807–815.
15. Xie W, Santulli G, Reiken SR, et al. Mitochondrial oxidative stress promotes atrial fibrillation. Sci Rep. 2015;5:11427.
16. D’Ascia SL, D’Ascia C, Marino V, et al. Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy. Int J Clin Pract. 2011;65:1149–1155.
17. Xie W, Santulli G, Guo X, et al. Imaging atrial arrhythmic intracellular calcium in intact heart. J Mol Cell Cardiol. 2013;64:120–123.
18. Chirinos JA, Castellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005;2:525–529.
19. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. J Am Coll Cardiol. 2003;42:191–196.
20. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1973–1980.
21. Adams KJ, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46:497–504.
22. Juurlink DN, Mamdani M, Kopp A, et al. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–1658.